NewAtlantis Labs transforms marine ecosystems into productive natural assets for sustainable ocean conservation.

10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

A-Alpha Bio is a provider of cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio utilizes its proprietary AlphaSeq technology to map protein-protein interactions at a high scale and resolution. This technology can identify and quantify interactions between thousands of protein pairs simultaneously. By providing detailed maps of protein interactions, A-Alpha Bio aids in the identification of potential drug targets and the understanding of disease mechanisms. This can significantly streamline the process of discovering new therapeutics. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Abbott is engaged in pharmaceuticals and manufacturing healthcare products. It developed the first HIV blood-screening test. Its product portfolio includes Norvir, a treatment for HIV, Synthroid, a synthetic thyroid hormone, Depakote, an anticonvulsant drug, and Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and more.

AbbVie is a biopharmaceutical company that develops pharmaceuticals and medical devices. The company provides products and services to therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology advancing treatments across various therapeutic areas.

AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner. With the integrated AbCellera platform, our experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set our partners up for enduring success.  We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Engineering the future of precision radio­therapeutics Abdera is combining advanced antibody engineering with radiotherapeutics to attack cancer in bold new ways.

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores the Chromeo Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while reatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of genetic medicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.